In a new job - June 11, 2014
New CMO for Oncos Therapeutics
Finnish Oncos Therapeutics Ltd has appointed Dr Magnus Jaderberg, M.D, Ph.D, as Chief Medical Officer. Dr Jaderberg joined Oncos Therapeutics on June 1, 2014. “We are very happy to announce the recruitment of Magnus to our team. He will bring strategic expertise and knowledge to our prioritized research and clinical development of novel cancer immune therapies”, […]
Drug Development Pharma - June 10, 2014
Medivir launches Olysio in the Nordic countries
Medivir has announced that its NS3/4A protease inhibitor Olysio will be available in all of the Nordic countries within the next few weeks. Treatment with Olysio began in Sweden in late May, followed by Finland and Denmark, where the first patients recently began their treatment. “It is immensely gratifying to now be able to offer a new […]
Collaboration - June 10, 2014
Beactica and Medivir in drug discovery collaboration
The Swedish fragment-based drug discovery company has entered into an agreement with Medivir. Under the agreement, Beactica will use its proprietary discovery platform to identify novel hits against a disease-relevant protease of therapeutic interest to Medivir. Financial terms of the agreement have not been disclosed. “We are pleased that Medivir has selected Beactica to advance one […]
Clinical Trials - June 9, 2014
Clinical study with Diamyd Medical’s diabetes vaccine fully recruited
All participants have been included in a Phase II clinical study, DIABGAD-1, in which Diamyd Medical’s diabetes vaccine Diamyd, in a unique combination with other drugs, is tested in children and adolescents recently diagnosed with type 1 diabetes. The first results from the researcher initiated study will thereby be available in the beginning of 2015. […]
Uncategorized - June 5, 2014
Swedish clinical research gets boost from Wallenberg
The Knut and Alice Wallenberg Foundation invests up to SEK 600 million during a ten-year period in the program Wallenberg Clinical Scholars. The aim with the boost is to maintain high quality in healthcare with cutting-edge clinical research in Sweden to keep up with the international competition. “Our objective is to boost Swedish clinical research by […]
Acquisition - June 5, 2014
Small Uppsala company in large deal
The smaller family company Namtall, a sister company to Medeca Pharma AB, has entered a large deal with pharmaceutical giant Valeant Pharmaceuticals. The deal, worth SEK 760 million (USD 115 million) plus royalties, regards the licensing rights for the sales of adrenalin pens for the treatment of allergic reactions. The medtech company Namtall from Uppsala […]
